Lupus
Dapirolizumab pegol superior to placebo, may represent a ‘novel treatment’ for lupus
WASHINGTON — The novel CD40L inhibitor dapirolizumab pegol bested placebo in multiple systemic lupus erythematosus outcomes, including disease activity and steroid tapering, at 48 weeks, according to data presented at ACR Convergence 2024.
Post-exertional malaise assessment ‘becoming more important’ for long COVID in rheum care
WASHINGTON — Approximately 20% of patients meeting the 2016 fibromyalgia criteria report post-exertional malaise, which itself may be key to understanding both long COVID and fatigue in patients with rheumatic diseases, according to data.
Woman presents for second opinion regarding medication use
A 32-year-old woman was referred by the rheumatology service for a second opinion regarding high-risk medication use evaluation.
Triamcinolone, methylprednisolone avoid prednisone’s fracture risk ‘trap’ in lupus
WASHINGTON — Although even low-dose prednisone significantly increases the risk for fracture in systemic lupus erythematosus, there is no increased risk from intramuscular triamcinolone or intravenous methylprednisolone, said a speaker.
Low Childhood Opportunity Index score may drive inequitable outcomes in pediatric lupus
WASHINGTON — Children with lupus from areas of lower socioeconomic opportunity experience more severe disease complications and poorer outcomes than those from higher opportunity areas, according to data presented at ACR Convergence 2024.
Addressing economic insecurities ‘could improve’ patient reported outcomes in lupus
WASHINGTON — Addressing economic insecurities through a social worker “could improve” physical function and other patient reported outcomes in systemic lupus erythematosus, according to a speaker at ACR Convergence 2024.
Models to predict lupus based on genetics, lifestyle perform ‘very well in all situations’
WASHINGTON — A model predicting the development of systemic lupus erythematosus, based on genetic, lifestyle and environmental factors, was successfully validated in a large cohort, according to data presented at ACR Convergence 2024.
Herpes zoster vaccine effective, shows ‘no signs’ of increased severe flare risk in lupus
WASHINGTON — Herpes zoster vaccination is effective in patients with systemic lupus erythematosus and multiple sclerosis, without increasing the risk for severe lupus flares, according to data presented at ACR Convergence 2024.
Black children with lupus have higher disease activity, less likely to achieve low activity
Black and multiracial children with systemic lupus erythematosus demonstrate higher disease activity and are less likely to achieve low disease activity compared with white children, according to data published in Arthritis Care & Research.
Highest, lowest vitamin D levels predict adverse pregnancy outcomes in lupus
Among pregnant women with systemic lupus erythematosus, those who demonstrate either high or low levels of serum vitamin D are more likely to experience miscarriage, preterm delivery and other adverse outcomes, according to data.